Strength Training Effects on Muscle in Adults Using GLP-1 Medication
Tests strength training in adults aged 50 and older taking GLP-1 weight-loss medication.
Key facts
- Who runs it
- Virginia Polytechnic Institute and State University
- Where
- Blacksburg, United StatesSee the site
- Trial code
- Registry title
- Strength Training Response of Muscle in GLP-1 Users
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 8 Oct 2025
- Expected to end
- May 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Strength Training
- Wait first, then strength training
- Record updated
- 21 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 and older who started GLP-1 medicine (Wegovy or Zepbound) within the last month. It studies muscle, balance and fall risk with strength training.
- Age
- 50 years and older
- Sex
- All sexes can join.
- Earlier treatment
- People must be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less.
Main reasons for not taking part
- Age under 50
- Weight over 300 lb (136 kg)
- Osteoporosis
- Active metabolic, neoplastic, or cardiovascular disease
- Unable or unwilling to give consent
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age, 50y+
- Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
- Weight <300 lb
- Pass a health and exercise readiness screening
Who cannot take part
- Active metabolic, neoplastic, or cardiovascular disease
- Age <50
- Weight >300 lb
- Osteoporosis
- Unable or unwilling to provide consent
Where in United States
- Virginia TechBlacksburg, United StatesContact: Kevin DavyTaking people
About the trial
What the trial wants to find out
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.
The 2 groups in the trial
- Strenth TrainingTreatment being tested
Participants will undergo strength training 3 times per week for 14 weeks.
Treatment: Strength Training
- Waitlisted controlOther group
Participants will have no strength training intervention for 14 weeks. Participants will be offered the same 14-week strength training program after the initial 14 weeks.
Treatment: Wait first, then strength training
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Strength Training Response of Muscle in GLP-1 Users
- Plain-language title
- Strength Training Effects on Muscle in Adults Using GLP-1 MedicationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 January 2026